Nine patients with heterozygous familial hypercholesterolaemia were treated for eight weeks with either 40 mg pravastatin or placebo under double blind conditions. Six patients received pravastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Treatment with pravastatin resulted in a significant decrease in plasma cholesterol caused by a decrease in low density lipoprotein cholesterol (LDL-c) of 30% (p<0.005). We determined the effect of this medication on the lithogenicity of bile. Cholesterol saturation index of fasting gall bladder bile decreased with 23% (p<0-01) from 1-06 to 075 during treatment with pravastatin. A reduction of 24% (p<0-01) in molar percentage of biliary cholesterol was seen. After treatment the total bile acid excretion in faeces and the molar percentage of biliary bile acids were not significantly changed, suggesting that pravastatin does not influence bile acid biosynthesis to a significant extent. These findings indicate that treatment with pravastatin can decrease the incidence and complications of cholesterol gail stones.
Pravastatin (eptastatin, CS-514, SQ 31-000), is a new hypocholesterolaemic agent which effectively lowers total plasma cholesterol, by competitive inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in cholesterol synthesis.' 2 Next to lowering plasma cholesterol this drug can also influence biliary cholesterol excretion. 3 A reduction in cholesterol synthesis can theoretically lead to changes in bile acid synthesis, resulting in unpredictable changes in bile composition. Supersaturation of bile with cholesterol predisposes to formation of gall stones. 4 Other systemic lipid lowering drugs, like clofibrate and gemfibrozil increase cholesterol saturation of bile, thereby enhancing the risk of gall stone formation.56 Data on the effect of HMG-CoA reductase inhibitors on bile composition in animals are limited and give conflicting results. Tsujita showed that pravastatin induces a reduction of the cholesterol saturation index (CSI) in dogs by decreasing the biliary neutral sterols and cholesterol, without effects on phospholipids and bile acids.7 In another study Kempen et al found in rats that compactin, another HMGCoA reductase inhibitor, resulted in a decrease of bile cholesterol. In that study, however, bile acid secretion decreased as well. 8 The gall bladder bile of six patients treated with pravastatin, showed a significant decrease in cholesterol saturation index from 1-06 to 0-75 (23%, p<001) ( Figure) . The most impressive decreases in cholesterol saturation index (48, 40 and 35%) were seen in three patients having indexes above 1-0 before therapy (indicating an increased risk for gall stone formation). In faeces total bile acid excretion was not influenced by pravastatin treatment (Table II) . In bile the molar percentage of bile acids was not changed either, while the molar percentage of biliary cholesterol was significantly reduced by 24% (p<0001). As expected the concentration of phospholipids did not change. The placebo treated patient did not show any effect on either the gall bladder bile composition, or the faecal bile acid excretion (Table II) . None of the patients showed any side effect. 
